A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. Issue 10 (1st October 2000)

• Record Type: Journal Article
• Authors: Crook, M A; Lynas, J; Wray, R
• Is Part Of: Journal of clinical pathology. Volume 53:Issue 10(2000)
• Page Start: 796
• Page End: 797
• Publication Date: 2000-10-01
• Subjects: fibrate -- high density lipoprotein-cholesterol -- renal function; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jcp.53.10.796
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : There have been a handful of reports in the literature of a paradoxical decrease in serum high density lipoprotein (HDL)-cholesterol in patients on fibrate drugs. The reason for this decline in cardioprotective HDL-cholesterol is not known and may have potential deleterious effects on the patient. This report describes a decrease in serum HDL-cholesterol in a patient on both simvastatin and bezafibrate. This patient also developed abnormal renal function, probably interstitial nephritis. In addition, the literature of fibrate induced serum HDL-cholesterol decline is reviewed and possible mechanisms for this phenomenon discussed.